Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Anteris or the Company ) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart ...
The Manila Times

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial”)

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart ...
Endovascular Today

Refresher: The 2023 NCD for Carotid Stenting

What physicians need to know about the expanded carotid artery stenting coverage, including choice of therapy, shared ...
Endovascular Today

Carotid Artery Stenting Training: How to Ensure Preparedness and Proficiency

Dr. Kenneth Rosenfield discusses proficiencies required for performing transfemoral carotid artery stenting and how best to ...
News Medical

HEMASHIELD PLATINUM Woven Double Velour Vascular Grafts from Maquet

HEMASHIELD PLATINUM Woven Double Velour Grafts are collagen-impregnated and come in straight, one-branch, or multi-branch graft configurations for aortic repair. Trusted for more than 20 years, ...

Cardiologist warns ‘poor oral hygiene may raise heart disease risk’: ‘Yes, there’s a microbiome that goes all the way from your nose…’

Dr Prakash informs that chronic or untreated sinus infections—whether bacterial or fungal—can lead to persistent low-grade ...